Despite decades of scientific breakthroughs, the pharmaceutical industry faces a sobering reality: nine out of ten drugs that enter clinical trials never make it to patients. This staggering failure rate, combined with costs exceeding $1-2 billion and timelines stretching 10-15 years per approved drug, reveals a system in crisis.
A Broken Funnel
The current drug development paradigm operates like a massive, expensive funnel. It begins with high hopes in the discovery phase, where researchers identify promising therapeutic targets and optimise candidate molecules. These candidates then navigate preclinical testing and multiple phases of clinical trials, with the funnel narrowing dramatically at each stage.
The process prioritises safety validation early and a necessary precaution, certainly. But here’s the catch: clear evidence that a drug actually works in humans only emerges after expensive, time-consuming trials.
Where It All Goes Wrong
When drugs fail in clinical trials, the reasons fall into predictable patterns:
- 40-50% fail due to lack of efficacy: the drug simply doesn’t work in humans, despite looking promising in laboratory and animal studies
- ~30% fail due to toxicity or unmanageable side effects
- The remainder are lost because the drug doesn’t stay in the body long enough to work and can’t reach the right tissues.
The disconnect between preclinical promise and clinical reality. A mere 3-4% of failures stem from insufficient understanding of the science itself. The vast majority fail because our preclinical models—primarily animal studies—cannot accurately predict how drugs will perform in human patients.
The Path Forward
This is where MicroTex enters the picture. Even when drug candidates target the right molecular pathways, they often fail in clinical trials not because the science is wrong, but because the drug doesn’t reach diseased tissues in sufficient concentrations—or worse, accumulates in healthy vital organs causing toxicity. Until now, directly measuring drug exposure and selectivity in human tissues before expensive clinical trials has been impossible. MicroTex is a decision-enabling platform that fills this critical gap, providing tissue-level drug exposure data that helps researchers identify which indications are most likely to succeed in clinical trials—before committing hundreds of millions to late-stage testing.